Kailera Therapeutics (KLRA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Kailera Therapeutics (KLRA) is Moderate Underperform.

The composite score behind that read is -0.33, weighing +0.15 of bullish evidence against -0.40 bearish.

Kailera Therapeutics last closed at $10.83, -0.09% on the session.

Against the IVW growth benchmark the position is -0.70% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

17 graded predictions for KLRA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Kailera Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.41B.

StockMap tracks Kailera Therapeutics as the 115th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Kailera Therapeutics ranks 293rd of 365 in the group, against a group median of -0.21.